Rx (Prescription Medicine)
Fempro 2.5毫克片剂含有来曲唑，这是一种芳香化酶抑制剂，常用于治疗绝经后女性的激素受体阳性乳腺癌。它的作用机制是减少雌激素的产生，雌激素是一种能够促进某些乳腺癌生长的激素。
可能出现的副作用包括疲劳、食欲减退、关节疼痛或僵硬、恶心、呕吐、头晕、腹泻、便秘和出汗增多。如果这些症状持续或加重，请就医。
Fempro 2.5毫克片通常每日服用一次，餐前或餐后均可。请用水整片吞服，切勿掰开、咀嚼或压碎。每日同一时间服用有助于维持稳定的药物浓度。除非您的医疗保健提供者建议，否则请勿停止治疗。
如果您已知对来曲唑过敏，请勿使用此药。开始治疗前，请告知医生您是否有骨质疏松症、高胆固醇或肝脏疾病史。不建议孕妇或哺乳期妇女服用 Fempro 2.5 毫克片。
| Brand Name | |
|---|---|
| Pack Quantity | 10 Tablets, 30 Tablets, 60 Tablets, 90 Tablets |
| Country Of Origin | India |
| Medicine Form | Tablet |
| Medicine Type | Generic |
| Molecule | |
| Packaging Type | Strip |
| Rx Status | Rx (Prescription Medicine) |
| Strength | 25 Mg |
只有已购买此产品的登录客户才能发表评价。
其他品牌的 Letrozole 25 Mg — 同一活性成分且强度相同，但来自不同制造商。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
评价
目前还没有评价